Catalyst Pharmaceuticals, Inc. (FRA:CN2)

Market Cap	2.54B -5.4%
Revenue (ttm)	492.80M +25.6%
Net Income	185.43M +52.4%
EPS	1.46 +44.9%
Shares Out	n/a
PE Ratio	13.67
Forward PE	9.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	146
Open	20.50
Previous Close	20.30
Day's Range	20.50 - 20.50
52-Week Range	16.15 - 24.00
Beta	n/a
RSI	52.96
Earnings Date	Feb 25, 2026

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatmen...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 181
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CN2

Financial Performance

In 2024, Catalyst Pharmaceuticals's revenue was $491.73 million, an increase of 23.49% compared to the previous year's $398.20 million. Earnings were $163.89 million, an increase of 129.50%.

Financial numbers in USD